Prospective replication study implicates the catechol-O-methyltransferase Val158Met polymorphism as a biomarker for the response to morphine in patients with cancer

Matsuoka,Hiromichi; Makimura,Chihiro; Koyama,Atsuko; Fujita,Yoshihiko; Tsurutani,Junji; Sakai,Kiyohiro; Sakamoto,Ryo; Nishio,Kazuto; Nakagawa,Kazuhiko

doi:10.3892/br.2017.963

Prospective replication study implicates the catechol-O-methyltransferase Val158Met polymorphism as a biomarker for the response to morphine in patients with cancer

Authors:
- Hiromichi Matsuoka
- Chihiro Makimura
- Atsuko Koyama
- Yoshihiko Fujita
- Junji Tsurutani
- Kiyohiro Sakai
- Ryo Sakamoto
- Kazuto Nishio
- Kazuhiko Nakagawa
View Affiliations

Affiliations: Department of Psychosomatic Medicine, Kindai University Faculty of Medicine, Osaka 589‑8511, Japan, Department of Genome Biology, Kindai University Faculty of Medicine, Osaka 589‑8511, Japan, Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka 589‑8511, Japan
Published online on: August 8, 2017 https://doi.org/10.3892/br.2017.963
Pages: 380-384

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Genetic differences in humans cause clinical difficulties in opioid treatment. Previous studies indicate that a single nucleotide polymorphism in the catechol‑O‑methyltransferase (COMT) gene (rs4680; p.Val158Met) may present as a predictive biomarker for the response to morphine treatment. In our previous pilot exploratory study, patients with a G/G genotype were demonstrated to require a higher dose of morphine, compared with patients with A/A and A/G genotypes. In the present study, the aim was to replicate the findings in an independent cohort of opioid‑treatment‑naïve patients exhibiting various types of cancer. This prospective study was conducted from 2011 to 2012 at the Kindai University Faculty of Medicine. A total of 50 patients with opioid‑treatment naïve and histologically confirmed malignant neoplasms who were scheduled to undergo opioid treatment were evaluated in the present study. Assessments were conducted pre‑treatment (day 1), post‑treatment (day 1), and one week after treatment (day 8). The required dose of morphine on day 1 was significantly higher for patients with the G/G genotype of COMT, compared with those with the A/A and A/G genotypes (P=0.013). The results of the present study provide additional evidence that the COMT genotype may be a predictive biomarker for the response to morphine treatment.

View Figures

View References

1	Cleeland CS: Undertreatment of cancer pain in elderly patients. JAMA. 279:1914–1915. 1998. View Article : Google Scholar : PubMed/NCBI
2	Patrick DL, Ferketich SL, Frame PS, Harris JJ, Hendricks CB, Levin B, Link MP, Lustig C, McLaughlin J, Reid LD, et al: National Institutes of Health State-of-the-Science Panel: National Institutes of Health State-of-the-Science Conference Statement: Symptom management in cancer: pain, depression, and fatigue. July;15–17. 2002.J Natl Cancer Inst Monogr. 32:9–16, 2004.
3	Potter J and Higginson IJ: Pain experienced by lung cancer patients: A review of prevalence, causes and pathophysiology. Lung Cancer. 43:247–257. 2004. View Article : Google Scholar : PubMed/NCBI
4	Butler LD, Koopman C, Cordova MJ, Garlan RW, DiMiceli S and Spiegel D: Psychological distress and pain significantly increase before death in metastatic breast cancer patients. Psychosom Med. 65:416–426. 2003. View Article : Google Scholar : PubMed/NCBI
5	Bischoff K, Weinberg V and Rabow MW: Palliative and oncologic co-management: Symptom management for outpatients with cancer. Support Care Cancer. 21:3031–3037. 2013. View Article : Google Scholar : PubMed/NCBI
6	Chase DM, Huang HQ, Wenzel L, Cella D, McQuellon R, Long HJ, Moore DH and Monk BJ: Quality of life and survival in advanced cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol. 125:315–319. 2012. View Article : Google Scholar : PubMed/NCBI
7	Kelsen DP, Portenoy RK, Thaler HT, Niedzwiecki D, Passik SD, Tao Y, Banks W, Brennan MF and Foley KM: Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol. 13:748–755. 1995. View Article : Google Scholar : PubMed/NCBI
8	Turk DC, Sist TC, Okifuji A, Miner MF, Florio G, Harrison P, Massey J, Lema ML and Zevon MA: Adaptation to metastatic cancer pain, regional/local cancer pain and non-cancer pain: Role of psychological and behavioral factors. Pain. 74:247–256. 1998. View Article : Google Scholar : PubMed/NCBI
9	Lötsch J, Geisslinger G and Tegeder I: Genetic modulation of the pharmacological treatment of pain. Pharmacol Ther. 124:168–184. 2009. View Article : Google Scholar : PubMed/NCBI
10	Bell GC, Donovan KA and McLeod HL: Clinical implications of opioid pharmacogenomics in patients with cancer. Cancer Control. 22:426–432. 2015.PubMed/NCBI
11	Rakvåg TT, Klepstad P, Baar C, Kvam TM, Dale O, Kaasa S, Krokan HE and Skorpen F: The Val¹⁵⁸Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain. 116:73–78. 2005. View Article : Google Scholar : PubMed/NCBI
12	Rakvåg TT, Ross JR, Sato H, Skorpen F, Kaasa S and Klepstad P: Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain. 4:642008. View Article : Google Scholar : PubMed/NCBI
13	Reyes-Gibby CC, Shete S, Rakvåg T, Bhat SV, Skorpen F, Bruera E, Kaasa S and Klepstad P: Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 130:25–30. 2007. View Article : Google Scholar : PubMed/NCBI
14	Candiotti KA, Yang Z, Buric D, Arheart K, Zhang Y, Rodriguez Y, Gitlin MC, Carvalho E, Jaraba I and Wang L: Catechol-o-methyltransferase polymorphisms predict opioid consumption in postoperative pain. Anesth Analg. 119:1194–1200. 2014. View Article : Google Scholar : PubMed/NCBI
15	Klepstad P, Fladvad T, Skorpen F, Bjordal K, Caraceni A, Dale O, Davies A, Kloke M, Lundström S, Maltoni M, et al: European Association for Palliative Care Research Network: Influence from genetic variability on opioid use for cancer pain: A European genetic association study of 2294 cancer pain patients. Pain. 152:1139–1145. 2011. View Article : Google Scholar : PubMed/NCBI
16	Atkinson TM, Mendoza TR, Sit L, Passik S, Scher HI, Cleeland C and Basch E: The Brief Pain Inventory and its ‘pain at its worst in the last 24 hours’ item: Clinical trial endpoint considerations. Pain Med. 11:337–346. 2010. View Article : Google Scholar : PubMed/NCBI
17	Matsuoka H, Arao T, Makimura C, Takeda M, Kiyota H, Tsurutani J, Fujita Y, Matsumoto K, Kimura H, Otsuka M, et al: Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients. Oncol Rep. 27:1393–1399. 2012.PubMed/NCBI
18	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
19	Swarm R, Abernethy AP, Anghelescu DL, Benedetti C, Blinderman CD, Boston B, Cleeland C, Coyle N, Deleon-Casasola OA, Eilers JG, et al: NCCN Adult Cancer Pain: Adult cancer pain. J Natl Compr Canc Netw. 8:1046–1086. 2010. View Article : Google Scholar : PubMed/NCBI
20	Caraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L and De Conno F: Pain measurement tools and methods in clinical research in palliative care: Recommendations of an expert working group of the European Association of Palliative Care. J Pain Symptom Manage. 23:239–255. 2002. View Article : Google Scholar : PubMed/NCBI
21	National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) v4.03, . https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdfJune 14–2010
22	Montagna P: Recent advances in the pharmacogenomics of pain and headache. Neurol Sci. 28 Suppl 2:S208–S212. 2007. View Article : Google Scholar : PubMed/NCBI
23	Farrar JT, Polomano RC, Berlin JA and Strom BL: A comparison of change in the 0–10 numeric rating scale to a pain relief scale and global medication performance scale in a short-term clinical trial of breakthrough pain intensity. Anesthesiology. 112:1464–1472. 2010. View Article : Google Scholar : PubMed/NCBI
24	Tunbridge EM, Harrison PJ and Weinberger DR: Catechol-o-methyltransferase, cognition, and psychosis: Val¹⁵⁸Met and beyond. Biol Psychiatry. 60:141–151. 2006. View Article : Google Scholar : PubMed/NCBI
25	Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, Koeppe RA, Stohler CS and Goldman D: COMT val¹⁵⁸Met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 299:1240–1243. 2003. View Article : Google Scholar : PubMed/NCBI
26	Arnold BS, Alpers GW, Süss H, Friedel E, Kosmützky G, Geier A and Pauli P: Affective pain modulation in fibromyalgia, somatoform pain disorder, back pain, and healthy controls. Eur J Pain. 12:329–338. 2008. View Article : Google Scholar : PubMed/NCBI
27	Lee YH, Kim JH and Song GG: Association between the COMT Val¹⁵⁸Met polymorphism and fibromyalgia susceptibility and fibromyalgia impact questionnaire score: A meta-analysis. Rheumatol Int. 35:159–166. 2015. View Article : Google Scholar : PubMed/NCBI